pCAR-19B cells

BIOLOGICAL3 trials

Sponsors

Chongqing Precision Biotech Co., Ltd

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL

Phase 1

Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

CompletedNCT04888468

Chongqing Precision Biotech Co., LtdAcute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL

Start: 2019-11-05End: 2021-09-01Updated: 2022-03-18

Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Chongqing Precision Biotech Co., LtdAcute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia

Start: 2020-10-26End: 2022-03-28Target: 18Updated: 2021-05-17

Phase 2

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

RecruitingNCT05334823

Chongqing Precision Biotech Co., LtdAcute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL

Start: 2022-01-26End: 2029-07-01Target: 100Updated: 2026-09-15

Related Papers

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Blood2024-11-05

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Blood2022-11-15